Literature DB >> 7865179

Monoamine oxidase inhibition by the MAO-A inhibitors brofaromine and clorgyline in healthy volunteers.

C H Gleiter1, B Mühlbauer, R M Schulz, E Nilsson, K H Antonin, P R Bieck.   

Abstract

The present study compared the extent and duration of MAO inhibition by the selective and reversible MAO-A inhibitor brofaromine with the selective and irreversible MAO-A inhibitor clorgyline using amine pressor tests and excretion of urinary amine metabolites (MHPG, tryptamine). The pharmacological characterization of clorgyline as an irreversible and brofaromine as a reversible MAO-A inhibitor in clinically effective doses was confirmed in humans.

Entities:  

Mesh：

Substances：

Year:  1994        PMID： 7865179     DOI： 10.1007/bf01271570

Source DB:  PubMed          Journal:  J Neural Transm Gen Sect


  6 in total

1.  Dissociation of norepinephrine turnover from alpha-2 responses after clorgiline.

Authors:  R L Hauger; M Scheinin; L J Siever; M Linnoila; W Z Potter
Journal:  Clin Pharmacol Ther       Date:  1988-01       Impact factor: 6.875

2.  An improved procedure of 3-methoxy-4-hydroxyphenyl-ethylene glycol determination by gas-liquid chromatography.

Authors:  H Dekirmenjian; J W Maas
Journal:  Anal Biochem       Date:  1970-05       Impact factor: 3.365

3.  Monoamine oxidase inhibition by phenelzine and brofaromine in healthy volunteers.

Authors:  P R Bieck; L Firkusny; C Schick; K H Antonin; E Nilsson; R Schulz; M Schwenk; H Wollmann
Journal:  Clin Pharmacol Ther       Date:  1989-03       Impact factor: 6.875

Review 4.  Brofaromine--a selective, reversible, and short-acting MAO-A inhibitor: review of the pharmacological and clinical findings.

Authors:  H J Möller; G Wendt; P Waldmeier
Journal:  Pharmacopsychiatry       Date:  1991-03       Impact factor: 5.788

5.  Efficacy of moclobemide in different patient groups: a meta-analysis of studies.

Authors:  J Angst; M Stabl
Journal:  Psychopharmacology (Berl)       Date:  1992       Impact factor: 4.530

6.  Oral tyramine pressor test and the safety of monoamine oxidase inhibitor drugs: comparison of brofaromine and tranylcypromine in healthy subjects.

Authors:  P R Bieck; K H Antonin
Journal:  J Clin Psychopharmacol       Date:  1988-08       Impact factor: 3.153
  6 in total
  4 in total

Review 1.  Drug treatment of depression in the 1990s. An overview of achievements and future possibilities.

Authors:  H J Möller; H P Volz
Journal:  Drugs       Date:  1996-11       Impact factor: 9.546

2.  Steady-state pharmacokinetics and pharmacodynamics of CHF3381, a novel antineuropathic pain agent, in healthy subjects.

Authors:  Béatrice Astruc; Antoine Tarral; Philippe Dostert; Fabrizia Mariotti; Laura Fabbri; Bruno P Imbimbo
Journal:  Br J Clin Pharmacol       Date:  2005-04       Impact factor: 4.335

Review 3.  Brofaromine--a review of its pharmacological properties and therapeutic use.

Authors:  H P Volz; C H Gleiter; P C Waldmeier; M Struck; H J Möller
Journal:  J Neural Transm (Vienna)       Date:  1996       Impact factor: 3.575

Review 4.  Natural Products Inhibitors of Monoamine Oxidases-Potential New Drug Leads for Neuroprotection, Neurological Disorders, and Neuroblastoma.

Authors:  Narayan D Chaurasiya; Francisco Leon; Ilias Muhammad; Babu L Tekwani
Journal:  Molecules       Date:  2022-07-04       Impact factor: 4.927
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.